Last reviewed · How we verify
Osvaren film-coated tablets
Osvaren film-coated tablets is a Small molecule drug developed by Fresenius Medical Care Deutschland GmbH. It is currently in Phase 2 development.
At a glance
| Generic name | Osvaren film-coated tablets |
|---|---|
| Sponsor | Fresenius Medical Care Deutschland GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Osvaren film-coated tablets CI brief — competitive landscape report
- Osvaren film-coated tablets updates RSS · CI watch RSS
- Fresenius Medical Care Deutschland GmbH portfolio CI
Frequently asked questions about Osvaren film-coated tablets
What is Osvaren film-coated tablets?
Osvaren film-coated tablets is a Small molecule drug developed by Fresenius Medical Care Deutschland GmbH.
Who makes Osvaren film-coated tablets?
Osvaren film-coated tablets is developed by Fresenius Medical Care Deutschland GmbH (see full Fresenius Medical Care Deutschland GmbH pipeline at /company/fresenius-medical-care-deutschland-gmbh).
What development phase is Osvaren film-coated tablets in?
Osvaren film-coated tablets is in Phase 2.